USFDA permits Zydus Cadila to market Azithromycin for Oral Suspension USP
The drug will be manufactured at the group’s formulations manufacturing facility at Baddi.
Drug firm Zydus Cadila today said it has received approval from the US health regulator to market Azithromycin for Oral Suspension USP, used to treat bacterial infections, in the American market.
The company has received final approval from the US Food & Drug Administration (USFDA) for the drug, Zydus Cadila said in a statement.
The medication is used to treat respiratory infections, skin infections, ear infections and sexually transmitted diseases.
The drug will be manufactured at the group's formulations manufacturing facility at Baddi.
The Ahmedabad-based group now has 213 approvals from the USFDA.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)